Stocktoria
Traws Pharma, Inc. ONTX
Traws Pharma, Inc. (ONTX) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $2.8M at a 328.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ONTX | Traws Pharma, Inc. | 3/9 | — | 1.4 | — |
| RNAC | Cartesian Therapeutics, Inc. | 1/9 | -10.08 | — | -92.8% |
| UPB | Upstream Bio, Inc. | 2/9 | — | — | — |
| XBIO | Xenetic Biosciences, Inc. | 3/9 | — | — | — |
| TXMD | TherapeuticsMD, Inc. | 5/9 | — | — | — |
| GOVX | GeoVax Labs, Inc. | 1/9 | — | — | — |
| CAMP | Camp4 Therapeutics Corp | 3/9 | -4.88 | — | — |
About Traws Pharma, Inc.
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
FAQ
Is ONTX financially healthy?
Traws Pharma, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does ONTX pay a dividend?
No, Traws Pharma, Inc. does not currently pay a dividend.
How profitable is ONTX?
In FY2025, Traws Pharma, Inc. had a net margin of 328.7%.
What is ONTX's P/E ratio?
Traws Pharma, Inc.'s trailing price-to-earnings (P/E) ratio is about 1.4×, based on its latest annual earnings.
What is the analyst price target for ONTX?
The average Wall-Street price target for Traws Pharma, Inc. is $1.00, from 1 analysts (consensus: hold).
Is ONTX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Traws Pharma, Inc.: a Piotroski F-score of 3/9, a P/E of about 1.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.